This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Quidel's CEO Presents At Goldman Sachs Healthcare Conference (Transcript)

But certainly the seasonality doesn't bother us; it’s the volatility that is a big concern for us. Beginning in 2009, the first step in the process was to bring on board R&D talent, also business development talent. We began creating a pipeline basically from scratch and we focused on a couple of different areas; we focused on a next generation platform to stabilize our presence in the space in which we compete today and then we embarked on molecular diagnostic and the other and I certainly can talk a little bit more about that if you like.

We did effectively three deals if you will. We entered into a collaborative agreement with a company called BioHelix; BioHelix is in the R&D that has now created the world’s first handheld molecular device called AmpliVue and will be launching that first product here in the US in Q4. We also entered into an agreement with Northwestern University who had developed a novel extraction technology that will become the basis for the cartridge that goes into our integrated platform.

And then we also did an acquisition; we spent in early 2010, $130 million on a company called DHI, Diagnostic Hybrids. And the two major things that we got there were R&D synergies they had significant molecular diagnostic and assay development capability and they had an awesome group of scientists who are terrific at characterizing and developing monoclonal antibiotics.

Fast forward to last year, last year was a year in which we finally saw some of the fruits of all that investment. We had four assays cleared here in the United States and to be marketed. Each of those was a 510(k) clearance. And during the period, we also saw a number of technical issues so that in this year, 2012, we should see an acceleration in the topline -- an acceleration in terms of product development and currently we have five assays in clinical trials in the United States and so we expect to see a little bit of productivity gain this year is such that in 2013 we actually see topline acceleration.

2 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs